Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial

Drug and Alcohol Dependence

Volumn 94, Issue 1-3, 2008, Pages 281-284

  Chawarski, M C ^a   Mazlan, M ^b   Schottenfeld, R S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Substance Abuse Center   (Malaysia)

Author keywords

Buprenorphine treatment; Drug counseling; HIV risk reduction counseling

Indexed keywords

BUPRENORPHINE; DIAMORPHINE;

ABSTINENCE CONTINGENT TAKE HOME THERAPY; AMBULATORY CARE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG URINE LEVEL; EVIDENCE BASED MEDICINE; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAINTENANCE THERAPY; MALAYSIA; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT COUNSELING; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; URINALYSIS;

ADOLESCENT; ADULT; BUPRENORPHINE; COUNSELING; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEROIN DEPENDENCE; HIV INFECTIONS; HOME CARE SERVICES; HUMANS; MALE; MIDDLE AGED; NARCOTICS; PATIENT ACCEPTANCE OF HEALTH CARE; PILOT PROJECTS; RISK REDUCTION BEHAVIOR;

EID: 39149132076     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.11.008     Document Type: Article

References (20)

1. Amato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M., Mayet, S., 2004. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. The Cochrane Database of Systematic Reviews. CD 004147, 002004.
2. Chawarski M.C., Mazlan M., and Schottenfeld R.S. Heroin dependence and HIV infection in Malaysia. Drug Alcohol Depend. 82 (2006) 39-42
3. Chawarski M.C., Pakes J., and Schottenfeld R.S. Assessment of HIV risk. J. Addict. Dis. 17 (1998) 49-59
4. Chutuape M.A., Silverman K., and Stitzer M.L. Effects of urine testing frequency on outcome in a methadone take-home contingency program. Drug Alcohol Depend. 62 (2001) 69-76
5. Fiellin D.A. The first three years of buprenorphine in the United States: experience to date and future directions. JAMA 1 (2007) 62-67
6. Fiellin D.A., Pantalon M.V., Chawarski M., Moore B.A., Sullivan L.E., O'Connor P.G., and Schottenfeld R. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl. J. Med. 355 (2006) 365-374
7. Iguchi M.Y., Lamb R.J., Belding M.A., Platt J.J., Husband S.D., and Morral A.R. Contingent reinforcement of group participation versus abstinence in a methadone maintenance program. Exp. Clin. Psychopharmacol. 4 (1996) 315-321
8. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., and Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 40 (1995) 17-25
9. Kosten T.R., Schottenfeld R., Ziedonis D., and Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181 (1993) 358-364
10. Ling W., Wesson D.R., Charuvastra C., and Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry 53 (1996) 401-407
11. Mazlan M., Schottenfeld R.S., and Chawarski M.C. New challenges and opportunities in managing substance abuse in Malaysia. Drug Alcohol Depend. 25 (2006) 473-478
12. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., and O'Brien C.P. The effects of psychosocial services in substance abuse treatment. JAMA 269 (1993) 1953-1959
13. Montoya I.D., Schroeder J.R., Preston K.L., Covi L., Umbricht A., Contoreggi C., Fudala P.J., Johnson R.E., and Gorelick D.A. Influence of psychotherapy attendance on buprenorphine treatment outcome. J. Subst. Abuse Treat. 28 (2005) 247-254
14. Prendergast M.L., Urada D., and Podus D. Meta-analysis of HIV risk reduction interventions with drug abuse treatment programs. J. Consult. Clin. Psychol. 69 (2001) 389-405
15. Rothman A.J., and Salovey P. Shaping perceptions to motivate healthy behavior: the role of message framing. Psychol. Bull. 121 (1997) 3-19
16. Rothman A.J., Salovey P., Antone C., Keough K., and Martin D.C. The influence of message framing on intentions to perform health behaviors. J. Exp. Soc. Psychol. 29 (1993) 408-433
17. Schottenfeld R.S., Pakes J., O'Connor P., Chawarski M.C., Oliveto A., and Kosten T.R. Thrice-weekly versus daily buprenorphine maintenance. Biol. Psychiatry 47 (2000) 1072-1079
18. Schwartz R.P., Highfield D.A., Jaffe J.H., et al. A randomized controlled trial of interim methadone maintenance. Arch. Gen. Psychiatry 63 (2006) 102-109
19. Schwartz R.P., Jaffe J.H., Highfield D.A., Callaman J.M., and O'Grady K.E. A randomized controlled trial of interim methadone maintenance: 10-month follow-up. Drug Alcohol Depend. 86 (2007) 30-36
20. Stitzer M.L., Iguchi M.Y., and Felch L. Contingent take-home incentive: effects of drug use of methadone patients. J. Consult. Clin. Psychol. 60 (1992) 927-934